Teva launches generic drug for cystic fibrosis patients

Tobramycin inhalation solution launched; drug received FDA approval last month

JERUSALEM — Teva Pharmaceutical Industries has launched its generic version of a drug for patients with cystic fibrosis, the Israeli drug maker said Thursday.

Teva announced the launch of tobramycin inhalation solution, a generic version of Novartis' drug Tobi. The Food and Drug Administration approved Teva's product last month. The drug is used to treat CF in patients whose lungs contain bacteria called Pseudomonas aeroginosa.

Tobi had sales of about $350 million during the 12-month period that ended in June, according to IMS Health.


Login or Register to post a comment.